Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated at Piper Sandler

Piper Sandler assumed coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note issued to investors on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $72.00 price objective on the stock.

A number of other equities research analysts have also weighed in on MNPR. Rodman & Renshaw started coverage on Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 price objective for the company. HC Wainwright raised their price target on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

Monopar Therapeutics Stock Up 3.6 %

NASDAQ MNPR opened at $25.35 on Friday. The stock has a market cap of $133.80 million, a PE ratio of -12.87 and a beta of 1.23. The business has a 50 day moving average price of $21.84 and a two-hundred day moving average price of $10.70. Monopar Therapeutics has a fifty-two week low of $1.54 and a fifty-two week high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. Sell-side analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Karthik Radhakrishnan acquired 1,550 shares of the business’s stock in a transaction on Monday, October 28th. The shares were purchased at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the purchase, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at $25,187.50. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.